GLP-1-driven vitamin deficiency linked to rare brain disorder: Study

Researchers have identified a rare but potentially life‑threatening brain disorder in a small number of patients who were taking Ozempic, Wegovy and other glucagon‑like peptide‑1 (GLP‑1) receptor agonists. The drugs, which are approved for type 2 diabetes management and for weight loss, were linked to cases of acute neurological symptoms that progressed rapidly, prompting hospital admission and intensive care in some instances.

The study, conducted by a team of neurologists and pharmacovigilance specialists, documented a handful of patients who developed severe headaches, confusion, seizures, and in a few cases, signs of brainstem dysfunction. While the exact mechanism remains unclear, the researchers noted that the temporal association between drug initiation and symptom onset suggests a possible causal relationship. Regulatory agencies such as the U.S. Food and Drug Administration are reviewing the findings, and the manufacturers have issued a safety update urging clinicians to monitor for neurological signs in patients on these medications.

Although the incidence is extremely low relative to the millions of people prescribed GLP‑1 agonists, the discovery highlights the need for vigilance. Patients experiencing new or worsening neurological symptoms while on Ozempic, Wegovy, or similar agents should seek prompt medical evaluation. Ongoing research aims to clarify the pathophysiology and to determine whether specific risk factors predispose certain individuals to this adverse effect.